Myrtle Clinical|myrtleclinical.org
Operations · The Myrtle Magazine

Paying on milestones is not overseeing

Milestone payment proves a task was completed. It says nothing about whether the trial is being managed well.

By Hadas Nachmanson, founder of Myrtle Clinical · June 2026

"We only pay the CRO when they hit the milestone." I often hear this framed as oversight. I see it differently.

Milestone based payment measures whether a task was completed. It does not tell you whether the trial is being managed well. It does not tell you why the same issue keeps reappearing every week, whether timelines are slipping because of weak execution or unrealistic resourcing, whether a site needs another study coordinator, whether the CRA is overloaded, or whether the protocol was ever made truly usable for the people expected to follow it.

And when payment becomes the main control mechanism, people focus on protecting the metric rather than openly surfacing what is actually going wrong.

Real oversight is not about making vendors work under fear. It is about understanding what stands between the trial and success, and fixing it. Sometimes that means escalation. Sometimes stronger accountability. Sometimes more support, clearer processes, better communication, or additional resources where they are genuinely needed.

The goal is not to catch the CRO. The goal is to make the trial better. Better managed, better supported, better controlled, and far more likely to deliver reliable results.

By Hadas Nachmanson, Founder of Myrtle Clinical · LinkedIn

Running a trial through a CRO?

Myrtle Clinical is the independent clinical operations representative on the sponsor's side only: overseeing and managing the CRO and vendors so your trial stays on schedule, on budget, and inspection-ready.

Meet Myrtle Clinical →